Wird geladen...
Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma
BACKGROUND: Sorafenib and lenvatinib are first‐line systemic therapies for unresectable hepatocellular carcinoma (HCC). However, the criteria for their selection remain unclear. METHODS: We identified patients with unresectable HCC who were treated with sorafenib or lenvatinib between August 2009 an...
Gespeichert in:
| Veröffentlicht in: | JGH Open |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wiley Publishing Asia Pty Ltd
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7578287/ https://ncbi.nlm.nih.gov/pubmed/33102759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgh3.12339 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|